Brief: Tissue Repair Receives Response From FDA Which Clarifies Path To Phase 3 Trials

Tissue Repair

28/09/2022 02:47

Sept 28 (Reuters) - Tissue Repair Ltd  TRP.AX :
    * RECEIVES RESPONSE FROM FDA WHICH CLARIFIES PATH TO PHASE 3
TRIALS
    * BELIEVES THAT IT WILL BE ABLE TO OBTAIN APPROVAL TO
COMMENCE ITS
PHASE 3 CLINICAL TRIALS IN 2023

Source text for Eikon:  ID:nASX2rqfv6 
Further company coverage:  TRP.AX 
 ((Reuters.Briefs@thomsonreuters.com;))